Peptides · Regulatory
The July 23–24 PCAC meeting — what is actually on the table.
Four peptides on the agenda for day one (BPC-157, KPV, TB-500, MOTS-c), two on day two. A public comment window that closes July 9, 2026. Here is what each possible vote — include, exclude, or table — would mean for a Limitless patient, why CJC-1295 is not on this docket, and how to weigh in before the vote, not after.
Peptides · GI Inflammation
KPV — strong preclinical signal, missing human trials.
A three-amino-acid α-MSH fragment with a clean PepT1-mediated mechanism, two decades of consistent murine colitis data, and not a single completed human RCT. Why Limitless is watching but not prescribing — and exactly which conditions would have to be met after the July 23 PCAC vote for that posture to change.
Metabolic · Regulatory
GLP-1 compounding status — 503A vs. 503B in 2026.
The FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. What it changes for 503B outsourcing facilities, what it does not change for 503A patient-specific compounding, and the three lanes a Limitless patient sees today — including why retatrutide is not one of them.
Peptides · Evidence
Peptides — what's real, what's risky, what we prescribe.
A physician's response to the 2026 "peptide craze" skepticism — the CNN piece, Eric Topol's Substack, the Frontiers in Aging January review. The skeptics are right that marketing has outrun the trials. They are not right that the molecules don't work. Both can be true at once — and the physician's job is to live in that gap honestly. Three evidence tiers, six prescribing rules, and what we deliberately do not prescribe.
Hormones · Longevity
The TRAVERSE trial — why we are comfortable optimizing testosterone.
5,246 hypogonadal men, mean 33 months on therapy, no signal of MACE, no excess prostate cancer, a small atrial-fibrillation signal worth screening for. The randomized trial that finally settles the cardiovascular safety question — and how it shapes the Limitless approach to hormone optimization.
Peptides · Metabolic
Tesamorelin — what the 2026 meta-analysis actually shows.
A pooled five-trial meta-analysis published in 2026 reports a mean −27.7 cm² reduction in visceral adipose tissue and a +1.42 kg increase in lean body mass on standard 2 mg dosing. The signal is consistent across HIV and non-HIV populations, holds up on modern INSTI regimens, and is now coupled to an emerging cognitive endpoint. Here is what the data supports — and what it does not.
Peptides · Regulatory
BPC-157 at the FDA — the case the agency is actually evaluating.
BPC-157 returns to the PCAC on July 23, 2026, this time formally evaluated for inclusion on the 503A bulks list. The animal data is voluminous and consistent. The human data is thin but improving. Here is what the dossier in front of the committee actually contains, what the credible mechanisms are, and how Limitless prescribes BPC-157 inside that uncertainty.
Longevity · Metabolic
NAD+ — what the clinical evidence actually supports.
The mitochondrial biology is solid. The precursor RCTs (NR, NMN) raise NAD+ and move metabolic markers in expected directions. The IV pharmacokinetic data is unambiguous. The longevity-endpoint trials in humans do not exist. Here is the honest map of what NAD+ does and does not do — and how the Limitless 5×750 mg IV load plus SubQ maintenance protocol is structured around what the data actually supports.
Longevity · Cognitive · Metabolic
Daily tadalafil — one molecule, five systems.
Endothelial nitric oxide signaling sits underneath cardiovascular function, cognitive perfusion, urinary symptoms, erectile function, and exercise capacity. A 5 mg daily dose of an inexpensive, FDA-approved generic moves all five. The mechanism is unified, the literature is durable, and the clinical case for using it as a standing preventative protocol in adult men over 40 — barring contraindications — is unusually clean.